For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Explore Gilead Sciences' Q3 2025 earnings: strong HIV portfolio growth, Yeztugo's rapid launch, and raised guidance.

Shiv Sena (UBT) leader and Worli legislator Aaditya Thackeray has written to Chief Minister (CM) Devendra Fadnavis, urging ...

OHE’s educational mission is to support, sustain, and enhance the discipline of health economics through increasing its accessibility, awareness, impact, reach, and relevance. As a pioneering ...

ST Pharm recently presented on Primitegravir, a drug that may offer new possibilities for HIV treatment. The bio-manufacturer ...

It is believed the lenacapavir shot could end HIV/Aids in the country within 14 to 18 years if enough people were to take it.

The Health departmental officials said that “a new plan will be shared" for when the funding ends in March 2026.

One in ten clinics in South Africa — across 22 health districts in six provinces — could start to hand out a twice-a-year anti-HIV jab as early as February if the country’s medicines regulator ...

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...

The Red Ribbon Club of Pranab College, in collaboration with the college Students’ Union and Department of ...

An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa's medicines regulator. The approval helps to clear the way for a limited public sector ...